RxDoctor Payments Data

Chelsy Cavazos

Primary Care · McAllen, TXNPI 1750844023

Payments from drug & device makers

$949in general payments, 2019–2025

Across 39 payments — averaging $24.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$218
  • Lilly USA, LLC$186
  • Amgen$140
  • Astellas Pharma US Inc$85
  • Johnson & Johnson$79
  • Ironwood Pharmaceuticals, Inc$65
  • plus $177 from 4 others

What the payments were for

  • Food & beverage$83688%
  • Education$11312%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$949 in reported general payments places this provider in the 70th percentile of 563 primary care providers in Texas.

See all primary care providers in Texas

Medicare billing

Part B allowed, 2024
$1,202
Medicare patients
11
Services billed
25

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide77$110,556
JardianceEmpagliflozin19$26,953
LinzessLinaclotide24$24,224
XareltoRivaroxaban11$20,293
EliquisApixaban15$19,578
MyrbetriqMirabegron23$18,822
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog26$17,399
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$17,158
Breo ElliptaFluticasone/Vilanterol11$4,912
Omeprazole92$1,979
Gabapentin116$1,970
Diclofenac Sodium37$1,435
Fluticasone Propionate89$1,396
Albuterol Sulfate HfaAlbuterol Sulfate45$1,217
Levothyroxine Sodium165$1,122

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$218$110,55677 claims
AbbVieLinzess$37$24,22424 claims
Johnson & JohnsonXarelto$79$20,29311 claims
Astellas Pharma US IncMyrbetriq$85$18,82223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 563 primary care providers in Texas.

Other primary care in McAllen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →